vs
Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
American Assets Trust, Inc. is the larger business by last-quarter revenue ($110.6M vs $103.7M, roughly 1.1× Twist Bioscience Corp). American Assets Trust, Inc. runs the higher net margin — 6.1% vs -29.4%, a 35.5% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 1.8%).
Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
AAT vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $110.6M | $103.7M |
| Net Profit | $6.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 23.4% | -31.7% |
| Net Margin | 6.1% | -29.4% |
| Revenue YoY | 1.8% | 16.9% |
| Net Profit YoY | -16.3% | 3.4% |
| EPS (diluted) | $0.08 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.6M | — | ||
| Q4 25 | $110.1M | $103.7M | ||
| Q3 25 | $109.6M | — | ||
| Q2 25 | $107.9M | — | ||
| Q1 25 | $108.6M | — | ||
| Q4 24 | $113.5M | — | ||
| Q3 24 | $122.8M | — | ||
| Q2 24 | $110.9M | — |
| Q1 26 | $6.7M | — | ||
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $5.5M | — | ||
| Q1 25 | $42.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $16.7M | — | ||
| Q2 24 | $11.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | 52.0% | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.0% | — | ||
| Q4 24 | 61.3% | — | ||
| Q3 24 | 65.5% | — | ||
| Q2 24 | 63.6% | — |
| Q1 26 | 23.4% | — | ||
| Q4 25 | 21.1% | -31.7% | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 24.1% | — | ||
| Q1 25 | 66.3% | — | ||
| Q4 24 | 26.5% | — | ||
| Q3 24 | 30.8% | — | ||
| Q2 24 | 27.8% | — |
| Q1 26 | 6.1% | — | ||
| Q4 25 | — | -29.4% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 39.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.6% | — | ||
| Q2 24 | 10.7% | — |
| Q1 26 | $0.08 | — | ||
| Q4 25 | $0.06 | $-0.50 | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.70 | — | ||
| Q4 24 | $0.14 | — | ||
| Q3 24 | $0.28 | — | ||
| Q2 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.3M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $456.1M |
| Total Assets | $2.9B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.3M | — | ||
| Q4 25 | $129.4M | $197.9M | ||
| Q3 25 | $138.7M | — | ||
| Q2 25 | $143.7M | — | ||
| Q1 25 | $143.9M | — | ||
| Q4 24 | $425.7M | — | ||
| Q3 24 | $533.0M | — | ||
| Q2 24 | $114.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $456.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $638.1M | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.4B | — | ||
| Q2 24 | $3.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.72× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | 14.5% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.1M | $-24.8M | ||
| Q3 25 | $40.5M | — | ||
| Q2 25 | $49.2M | — | ||
| Q1 25 | $36.9M | — | ||
| Q4 24 | $207.1M | — | ||
| Q3 24 | $52.4M | — | ||
| Q2 24 | $59.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $94.9M | $-34.8M | ||
| Q3 25 | $23.1M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $20.4M | — | ||
| Q4 24 | $136.9M | — | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $43.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 86.2% | -33.5% | ||
| Q3 25 | 21.1% | — | ||
| Q2 25 | 26.3% | — | ||
| Q1 25 | 18.8% | — | ||
| Q4 24 | 120.7% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 39.3% | — |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 65.6% | 9.6% | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 19.3% | — | ||
| Q1 25 | 15.1% | — | ||
| Q4 24 | 61.9% | — | ||
| Q3 24 | 19.9% | — | ||
| Q2 24 | 14.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.98× | — | ||
| Q2 25 | 9.01× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.15× | — | ||
| Q2 24 | 4.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
